Table 2.
Summary of Tumor Responses with CAPTEM Treatment from the Analyzed Studies
| Study, Year | Patients (N) | mOS [95% CI] (Months) | mPFS [95% CI] (Months) | DCR | CR | PR | SD | PD |
|---|---|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | ||||
| Fine, 200535 | 6 | -- | -- | 5 (83) | 1 (17) | 2 (33) | 2 (33) | 1 (17) |
| Isacoff, 200636 | 16 | 8 (4–17) | -- | 13 (77) | 1 (6) | 9 (53) | 3 (18) | 3 (18) |
| Strosberg 201137 | 30 | 38 (32–46) | 13 (11–23) | 85 (74) | 1 (1) | 23 (20) | 61(53) | 31 (27) |
| Welin, 201138 | 25 | 25.3 (13.7–36.9) | 7.1 (3.6–10.6) | 6 (54.5) | 0 (0) | 1 (9) | 5 (45.5) | 5 (45.5) |
| Claringbold, 201274 | 34 | NR | 31 (21–33) | 31 (91) | 5 (15) | 13 (38) | 13 (38) | 3 (9) |
| Ganetsky, 201239 | 20 | -- | 16 | 3 (65) | 0 (0) | 6 (30) | 7 (35) | 7 (35) |
| Fine, 201340 | 18 | 83 (19–140) | 14 (4–18) | 15 (83) | 1 (6) | 10 (55) | 4 (22) | 3 (17) |
| Oberstein, 201341 | 18 | -- | 14 (4–18) | 15 (84) | 1 (6) | 10 (56) | 4 (22) | 3 (16) |
| Abbasi, 201442 | 21 | -- | 16.5 | 17 (80) | 0 (0) | 12 (57) | 5 (23) | 4 (19) |
| Fine, 201443 | 28 | 25 | 20 | 27 (97) | 3 (11) | 9 (32) | 15 (54) | 1 (3) |
| Ramirez, 201544 | 30 | -- | 11 | 22 (73) | 0 (0) | 10 (33) | 12 (40) | 8 (27) |
| Spada, 201523 | 58 | 37 (30–56) | 15 (10–21) | 92 (81) | 1 (1) | 37 (33) | 54 (47) | 22 (19) |
| Chaves, 201645 | 10 | 48 | -- | 5 (50) | 1 (10) | -- | 3 (30) | 1 (10) |
| Cives, 201646 | 143 | 73 (52–81) | 17 (15–25) | 127 (89) | 0 (0) | 77 (54) | 50 (35) | 16 (11) |
| Claringbold, 201675 | 30 | NR | 48 | 30 (100) | 4 (13) | 20 (67) | 6 (20) | 0 (0) |
| Crespo, 201647 | 21 | 8 (5–11) | 4 (4–5) | 12 (44) | 0 (0) | 1 (4) | 11 (42.3) | 10 (38.5) |
| Ramirez, 201648 | 29 | NR | 12 | 19 (65) | 0 (0) | 5 (17) | 14 (48) | 10 (35) |
| Crespo, 201749 | 65 | 38 (25–52) | 16 (11–22) | 58 (90) | 2 (3) | 29 (45) | 27 (42) | 10 (10) |
| Lamarca, 201750 | 60 | 27 (16-NR) | 10 (7–14) | 43 (71) | 0 (0) | 14 (23) | 29 (48) | -- |
| Owen, 201751 | 29 | 29.3 (17.7–45.3) | 13 (5.6–17) | 26 (90) | 0 (0) | 11 (38) | 15 (52) | 3 (10) |
| Chauhan, 201852 | 12 | -- | -- | 9 (75) | 0 (0) | 6 (50) | 3 (25) | 3 (25) |
| Campana, 201853 | 95 | 33 (20–46) | 10 (5.6–14.4) | 68 (71.6) | 0 (0) | 26 (27.4) | 42 (44.2) | 27 (28.4) |
| Smiroldo, 201854 | 27 | NR | 4 | 16 (59) | 0 (0) | -- | -- | -- |
| Soulen 201855 | 19 | NR | 38.5 (29.8–47) | 19 (100) | 3 (16) | 11 (58) | 5 (26) | 0 (0) |
| De Mestier, 201956 | 153 | 60.5 (54.3–66.8) | 18.3 (13.8–21.7) | 128 (84) | 4 (3) | 60 (39) | 64 (42) | 25 (16) |
| Rogowski, 201957 | 32 | 15.6 (8–22) | 7 (3–15) | 18 (56) | 0 (0) | 11 (34) | 7 (22) | 14 (44) |
| Sahu, 201958 | 32 | 24 (17–30.8) | 10 (3.7–16.2) | 20 (63) | 4 (13) | 11 (34) | 5 (16) | 12 (37) |
| Yordanova, 201959 | 11 | NR | 4 | 16 (59) | 0 (0) | -- | -- | -- |
| Al Toubaah, 202060 | 32 | -- | -- | 21 (67) | 0 (0) | 6 (18.7) | 15 (46.8) | 5 (15.6) |
| Al Toubaah, 202061 | 20 | 68 (35–101) | 13 (4–22) | 17 (85) | 0 (0) | 6 (30) | 11 (55) | 3 (15) |
| Chatzellis, 202062 | 79 | 103 (43–163) | 10 (6–14) | 47 (59) | 0 (0) | 23 (29) | 24 (30) | 28 (35) |
| De Mestier, 202063 | 100 | 75 (58.5–92) | 21.4 (12.5–27.4) | 87 (87) | 2(2) | 49(49) | 36 (36) | 13 (13) |
| Ostwal, 202064 | 24 | NR | 34 (22–46) | 18 (61) | 3 (10) | 14 (48) | 1 (3) | 6 (25) |
| Papaxoinis, 202065 | 33 | 30.4 (25.6–35) | 9 (4.6–13.4) | 25 (76) | 0 (0) | 6 (18) | 19 (58) | 8 (24) |
| Squires, 202066 | 30 | -- | 18 (9–31) | 29 (97) | 0 (0) | 21 (70) | 8 (27) | 1 (3) |
| Thomas, 202067 | 116 | 74 | 12 | 115 (77) | 3 (2) | 37 (25) | 75 (50) | 36 (23) |
| Wang W, 202068 | 151 | 22 (8–27) | 6 (4–14) | 17 (71) | 1 (4) | 7 (29) | 9 (38) | 7 (29) |
| Dogan, 202169 | 43 | -- | 18 | 32 (76) | 1 (3) | 16 (38) | 16 (38) | -- |
| Jeong, 202172 | 30 | NR (10.5-NR) | 5.9 (4–11) | 23 (77) | 1 (3) | 8 (27) | 14 (47) | 7 (23) |
| Liu, 202170 | 20 | 41 (17-NR) | 9 (3–16) | 13 (65) | 0 (0) | 7 (35) | 6 (30) | 7 (35) |
| Spada, 202171 | 114 | 40 (23–122) | -- | 43 (74) | 0 (0) | 13 (22) | 30 (52) | -- |
Abbreviations: NR, not reached; --, not available; mOS, median overall survival; mPFS, median progression free survival; DCR, disease control rate; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.